山东步长制药股份有限公司 关于拟向控股子公司增资的进展公告

Group 1: Investment and Capital Increase - On October 29, 2025, the company approved a capital increase of 3 million RMB to its subsidiary, Jinan Buchang Shengyuan Medical Equipment Co., Ltd., at a price of 1 RMB per share, raising its registered capital from 10 million RMB to 13 million RMB [2][3] - The capital increase agreement was formally signed on December 12, 2025, and the relevant details were disclosed on December 13, 2025 [2][3] Group 2: Business Operations and Licensing - Jinan Buchang Shengyuan Medical Equipment Co., Ltd. has completed the business registration changes and obtained a new business license, with the updated registered capital of 13 million RMB [3] - The company operates in various sectors, including the sale of medical devices, personal protective equipment, and health food, among others [3] Group 3: Drug Registration and Development - The company's wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., has withdrawn its application for the drug registration of "Empagliflozin Tablets" due to the need for further documentation [5][9] - The drug is intended for the treatment of type 2 diabetes, and the company has invested approximately 1.5 million RMB in its research and development [6][8]